Can tumor grade help predict recurrence better?
Part of Cancer, Skin clinical trials.
This study looks at whether combining tumor grade with the 21-gene recurrence score can better predict breast cancer recurrence. Researchers will review medical records from women treated between 2011 and 2023.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone receptor-positive, HER2-negative early-stage breast cancer.
- You were treated between January 2011 and December 2023.
- You have had the 21-gene Oncotype DX test done and your records are available.
- You are age 20 or older.
- Your breast cancer has not spread to other parts of the body (stage IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced MRI scans to better understand breast cancer grade and outlook. It aims to see if computer analysis of MRI images can help predict tumor behavior, which could guide treatment decisions.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
This trial studies whether younger, premenopausal women with early-stage, hormone-sensitive breast cancer can safely use hormone therapy alone after surgery, based on their tumor's gene activity score (Oncotype DX). It aims to find the best treatment approach based on your cancer's biology.
This study builds a “genome atlas” to better predict the chance that breast cancer will come back. It asks participants to share medical information and provide blood and tumor tissue samples, including samples kept in paraffin.
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.